“Peijia Medical” was established in early 2012, by returned oversea Chinese expert in professional medical device industry, providing R&D and production of interventional medical products. Peijia Medical is dedicated to research, production and sales of high-end medical device for heart valve disease treatment. The core technical team came from famous international and domestic companies in related industry, with valuable experience in innovation, R&D, quality system, production and sales management. The achievements include the success launches of the first domestic heart drug eluting stent and the first domestic intracranial embolization coil.
Investors 3
| Date | Name | Website |
| - | Grand Flig... | gfinvestme... |
| - | SDIC Fund ... | sdicfund.c... |
| 09.02.2022 | Matrix Par... | matrixpart... |
Mentions in press and media 11
| Date | Title | Description |
| 29.08.2024 | Peijia Medical's Strong Growth in 2024: A Deep Dive into Interim Results | Peijia Medical, a prominent player in China's medical device market, has unveiled its interim results for the first half of 2024. The numbers tell a compelling story of growth, resilience, and strategic execution. With a sharp focus on tran... |
| 28.08.2024 | Achieva Medical Entered into an Exclusive Distribution Agreement with NowYon Medical | SUZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced that its wholly-owned subsidiar... |
| 26.08.2024 | Peijia Medical Announces 2024 Interim Results | HONG KONG, Aug. 26, 2024 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced financial results for the six month... |
| 26.08.2024 | Peijia Medical Announces 2024 Interim Results | HONG KONG, Aug. 26, 2024 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced financial results for the six month... |
| 25.07.2024 | Peijia Medical's Licensing Partner, JenaValve Technology, Inc., is Expected to be Acquired by Edwards Lifesciences | Peijia to maintain exclusive rights in Greater China to commercialize JenaValve's Trilogy Transcatheter Heart Valve (THV) System SUZHOU, China, July 25, 2024 /PRNewswire/ -- Peijia Medical Limited (Peijia, (9996.HK)), a leading Chinese dome... |
| 17.06.2024 | Peijia Medical Reports Audited 2023 Financial Results and Resumes Trading | HONG KONG, June 17, 2024 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutic and neurointerventional procedural medical device markets, announced the publication of... |
| 17.06.2024 | Peijia Medical Reports Audited 2023 Financial Results and Resumes Trading | HONG KONG, June 17, 2024 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutic and neurointerventional procedural medical device markets, announced the publication of... |
| 27.10.2023 | Peijia Medical Presents Early Clinical Findings of GeminiOne® TEER Device at TCT 2023 | SUZHOU, China, Oct. 27, 2023 /PRNewswire/ -- Peijia Medical Limited (Peijia, (9996.HK)), a leading Chinese medical device player in transcatheter structural heart device and neurovascular device, presented its GeminiOne® TEER technology, al... |
| 01.09.2023 | Peijia Medical Announces 2023 Interim Results | HONG KONG , Sept. 1, 2023 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutic and neurointerventional procedural medical device markets, today announced financial r... |
| 01.08.2023 | Peijia Medical Announces First Chinese Patient Implanted with TaurusTrio™ Transcatheter Aortic Valve Replacement System | SUZHOU, China, Aug. 1, 2023 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutic and neurointerventional procedural medical device markets, announced on July 31, 202... |
Show more